Saturday, 24 October 2026 Updated 18 min ago
The News Engine
Latest
Health United States

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

According to CNBC, a drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

This health story centres on the United States. Names and organisations mentioned in the coverage include Amgen and AstraZeneca.

Why it matters

Health developments can affect patients, healthcare providers and public-health planning.

Key details

Location
United States · Americas
Reported by
CNBC
First reported
Key names
Amgen, AstraZeneca
Section
Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

Read the full story at CNBC

Spotted an error? Request a correction · How this summary was produced

Related Stories